Suggested remit: To appraise the clinical and cost effectiveness of maribavir within its marketing authorisation for treating refractory or resistant cytomegalovirus infection in people who have had a transplant.
Status In progress
Process STA 2018
ID number 3900

Provisional Schedule

Committee meeting: 1 07 July 2022
Expected publication 14 September 2022

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Takeda
Others Department of Health and Social Care
  NHS England
  NHS Hull CCG
  NHS South Manchester CCG
  Welsh Government
Patient carer groups Anthony Nolan
  Aplastic Anaemia Trust
  Black Health Agency for Equality
  Blood Cancer UK
  British Heart and Lung Transplant Association
  British Liver Trust
  Cystic Fibrosis Trust
  Kidney Care UK
  Kidney Research UK
  Leukaemia Cancer Society
  Leukaemia Care
  Lymphoma Action
  Myeloma UK
  National Kidney Federation
  Pumping Marvellous Foundation
  Sommerville Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Clinical Biochemists - Microbiology Section
  Association of Respiratory Nurse Specialists
  British Association for the Study of the Liver
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Infection Association
  British Renal Society
  British Society for Haematology
  British Society of Blood and Marrow Transplantation
  British Society of Gastroenterology
  British Transplantation Society
  Health Lumen
  Immunodeficiency UK
  Infection Prevention Society
  Interstitial Lung Diseases Interdisciplinary Network
  Microbiology Society
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Cardiothoracic Surgery in Great Britain and Ireland
  Solid Organ Transplant Pharmacists Association
  UK Clinical Pharmacy Association
  UK Clinical Virology Network
  UK Kidney Association
  UK Renal Pharmacy Group


Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord Healthcare (valganciclovir)
  Aurobindo Pharma - Milpharm (valganciclovir)
  Cheplapharm Arzneimittel (ganciclovir)
  Cipla (valganciclovir)
  Clinigen Healthcare (foscarnet)
  Glenmark Pharmaceuticals (valganciclovir)
  Mylan (valganciclovir)
  Roche (valganciclovir)
  Thea Pharmaceuticals (ganciclovir)
  Tillomed Laboratories (cidofovir)
  Zentiva (valganciclovir)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services – Jehovah’s Witnesses
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Cystic Fibrosis and Genetic Disorders Group
  Cochrane Haematological Malignancies Group
  Cochrane Heart Group
  Cochrane Infectious Diseases Group
  Cochrane Kidney and Transplant Group
  Cochrane Lung Cancer Group
  Genomics England
  Leukaemia Busters
  Leukaemia UK
  MRC Clinical Trials Unit
  National Heart and Lung Institute
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
26 October 2021 Invitation to participate
22 October 2021 In progress. Appraisal in progress.
14 June 2021 (13:00) Scoping workshop
19 April 2021 - 18 May 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 May 2021 Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late-October 2021. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance